Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1408 - Development of a Nomogram for Predicting Survival in Microsatellite Stable Patients with Resected Colorectal Cancer


24 Nov 2018


Poster display - Cocktail


Targeted Therapy

Tumour Site

Colon and Rectal Cancer


Yaqi Li


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


Y. Li1, J. Peng1, D. Huang2, X. Ma1, S. Cai1

Author affiliations

  • 1 Department Of Colorectal Surgery, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Department Of Pathology, Shanghai Cancer Center Fudan University, 200032 - Shanghai/CN


Abstract 1408


The benefits of adjuvant chemotherapy remain controversial in microsatellite stable (MSS) stage II resected colorectal cancer (CRC) patients. In this study, we constructed an overall survival (OS) prediction model for this subgroup, integrating a combination of molecular and clinical predictors.


Variables with p-values < 0.05 were entered into multivariate analyses using Cox stepwise regression model to select independent predictors as input for OS prediction nomogram. A final model was selected using a backward step-down process, which used Akaike Information Criterion as a stopping rule. The probability of 3-year and 5-year survival can be obtained by summing up the total score and locating it on the total point scale.


We performed targeted sequencing on surgically resected tumor tissue of 122 stage II MSS patients, defined as having less than 15% length-instable loci, using a panel which allows for simultaneous detection of MSI status and mutation in 41 CRC-related genes. Among them, 23, 30 and 69 patients were diagnosed with proximal, distal and rectal cancer, respectively. To predict the probability of 3-year and 5-year survival, we constructed a nomogram incorporating the significant prognostic factors, including APC, ATM, BRAF, PTEN, TP53 (LOF), mutation count (high: >3, low: < =3), age, CEA, and the location of the tumor. The actual and predicted survivals were in an excellent agreement, reflected by a C-index of 0.887 (95% CI: 0.816-0.957). Furthermore, Kaplan-Meier curves for survival outcomes showed significant distinction (p < 0.001) after stratifying our cohort into low, median and high risk groups according to total score obtained from our nomogram. Our data also demonstrated high risk patients who received adjuvant chemotherapy are associated with a better OS (p = 0.004). Low and median risk patients did not benefit from adjuvant chemotherapy, reflected by comparable OS.


We developed a nomogram model for predicting survival of MSS patients with stage II resected CRC. It can potentially serve as complementary method for clinicians to identify subgroups necessitating adjuvant therapy.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Fudan University Shanghai Cancer Center.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.